Pfizer supports antibody for peripheral arterial disease
UK-based biotechnology company IsomAb has announced the nomination of a development candidate for peripheral arterial disease (PAD), therapeutic antibody ISM-001.
ISM-001 is designed to neutralise VEGF-A165b, the anti-angiogenic VEGF-A splice isoform which acts as a brake on development of new blood vessels leading to chronic limb threatening ischaemia (CLTI).
The company has also entered into a strategic collaboration with Pfizer Ignite to support preclinical development and IND-enabling studies for ISM-001.
Pfizer Ignite is an end-to-end service for biotech companies with therapeutics in Pfizer’s strategic focus areas that leverages Pfizer’s R&D capabilities, scale and expertise to accelerate the development of breakthrough therapies.
However, IsomAb will retain ongoing decision-making autonomy and full rights to the programme throughout the collaboration.
Jackie Turnbull, CEO of IsomAb Ltd, said: “Today’s announcement represents an important milestone for IsomAb and we continue to be encouraged by the potential of ISM-001 as a first-in-class treatment for patients with PAD, especially type 2 diabetics with CTLI at high risk of amputation. We appreciate the devastating loss of losing a limb and the impact on the lives of patients who have very limited treatment options. Given Pfizer’s strong commitment, extensive capabilities and deep expertise in developing new therapeutics, we are proud to partner with them to support the development of ISM-001.”
Kathy Fernando, SVP, Global Head of Pfizer Ignite, added: “We look forward to collaborating with IsomAb to advance the preclinical and IND-enabling studies for ISM-001. Pfizer has a strong history developing and implementing trials for vascular diseases, and we plan to leverage this expertise to support and advise IsomAb on their journey to translate compelling science into a potential new first-in-class treatment option for patients with peripheral arterial disease.”
Diana Spencer, Senior Digital Content Editor, DDW
